Matter Bio
DNA damage repair, cancer removal
repairingbacterial therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
C-RWHF
DNA damage repair, cancer removal
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This episode is live on Substack 14 days before it premieres on Youtube. For early access, feel free to explore it there. https://www.razibkhan.com/p/chris-bradley-better-science-for https://razib.substack.com This is where you will find all the podcasts from Razib Khan's Substack and original video content. Today Razib talks to Chris Bradley, a serial entrepreneur and the CEO and Co-Founder of Matter Bio, a company dedicated to preserving genome integrity and addressing the root causes of aging. With a multidisciplinary background spanning neuroscience, cell biology, and computer science, Bradley aims to translate early-stage biotech concepts into practical therapies that can extend human lifespan Matter Bio is focused on diagnosing, quantifying, and repairing the structural variations and mutations that accumulate in human DNA. Bradley has BS is neuroscience and cell biology from Rutgers and a MS in computer science from New York University. The discussion first aims to focus o
Christopher Bradley is a serial entrepreneur who has dedicated himself to solving aging after his last startup Mana Health was acquired by NBC Universal. His company Matter Bio is developing therapies to enhance DNA damage repair to slow the rate of aging, and to treat cancer through novel bacterial delivery mechanisms. In today’s conversation we discuss the theory of aging as information loss, which Chris contends is primarily mediated through DNA damage, how to unlock new approaches for longevity through large scale genomics studies, and the evolving business of biotech. #longevity #podcast
Christopher Bradley is a serial entrepreneur who has dedicated himself to solving aging after his last startup Mana Health was acquired by NBC Universal. His company Matter Bio is developing therapies to enhance DNA damage repair to slow the rate of aging, and to treat cancer through novel bacterial delivery mechanisms. In today’s conversation we discuss the theory of aging as information loss, which Chris contends is primarily mediated through DNA damage, how to unlock new approaches for longevity through large scale genomics studies, and the evolving business of biotech. 0:00 Intro 2:13 Largest study ever of genes for longevity 06:49 DNA damage as a driver of aging 14:10 Counter-arguments against the DNA thesis 25:16 Cancer isn't aging 27:53 How Matter Bio is targeting DNA damage to extend lifespan 35:15 Stem cell therapies 41:03 Different pathways for managing DNA damage 50:28 Sex ed (or what we can learn from germline rejuvenation) 55:14 What to expect from Matter Bio in the fut
Chris Bradley is health and biotech entrepreneur and co-founder of Matter Bio. Matter Bio is a biotech company working on longevity and cancer research. We get into the real mechanisms of aging, how Matter Bio is using bacteria as a biological Trojan horse to target tumors, and then zoom out into the Fermi Paradox, the singularity, and where AI and biology are headed. 🔗 Learn more about Matter Bio: https://www.matter.bio/ 🔗 Connect with Chris on LinkedIn: https://www.linkedin.com/in/christopher-bradley-303b4516 Timestamps: 00:00 – Introduction & Chris's background 02:15 – From pre-med to computational neuroscience to entrepreneurship 08:34 – Why Chris got obsessed with longevity and the Singularity 10:09 – Why biology is so hard to innovate in (vs. software) 15:00 – Where are we on the curve for biotech and aging research? ~20:00 – The information theory of aging where is "time" stored in the body? ~26:00 – Treating cancer with bacteria: how it works ~31:00 – The Trojan horse mecha
Discover how Matter Bio, co-founded by George Church, is revolutionizing aging research by studying the DNA of long-lived animals. Learn how their breakthrough genetic insights could lead to therapies that extend human healthspan and combat age-related diseases. #Longevity #GeorgeChurch #MatterBio #Biotech #AgingResearch #GeneTherapy #AntiAging #Healthspan #Genomics #Biotechnology #LifeExtension
The Future of Precision Medicine will lead to targeted treatments, better outcomes. Moderator: Tom Zuber (Managing Partner, Zuber Lawler LLP) Panelists (L - R): Matt Scholz (Founder and CEO, Oisín Biotechnologies), Reena Bhargava, MD, FACP (Co-Founder and CEO, BioTrax AI), Chris Bradley, PhD (CEO, Matter Bio)
Methuselah and Lazarus: The End of Sickness and Death at The World Forum 2025 Is aging inevitable—or is it just another disease to be cured? In this visionary panel, world-leading scientists and biotech innovators explore the frontiers of longevity research and the possibility of radically extending human healthspan. David Sinclair, renowned Harvard biologist and pioneer in epigenetics, joins Chris Bradley and Dr. Samim Sharifi of Matter Bio, alongside author and scientist Andrew Steele, to dissect the biological roots of aging, DNA repair mechanisms, and the potential to reprogram the body at a cellular level. From scientific breakthroughs to ethical dilemmas, the panel also tackles investment challenges and the regulatory hurdles facing the next era of medicine. With billions spent on treating age-related disease, could a world without sickness and death become reality? Speakers: David Sinclair – Professor, Harvard Medical School, expert in aging and epigenetics Chris Bradley – C
How can genome integrity slow aging? 🧬 Join Chris Bradley at #LongevitySummitDublin to explore DNA repair & mutation reversal. 📅 July 2-4, 2025 | Trinity College Dublin 🎟 Early Bird ends March 10! → https://longevitysummitdublin.com/buy-ticket/ #LongevityScience #Biotech #HealthyAging
Chris Bradley is a serial entrepreneur with a background in neuroscience, cell biology, and computer science. He is the founder and CEO of Matter Bio, a quadraScope portfolio company working on diagnosing, preventing, and treating diseases associated with the loss of genetic information. Learn more about Matter Bio: https://matterbio.com Learn more about quadraScope: https://quadrascope.com Chris' LinkedIn profile: https://www.linkedin.com/in/christopher-bradley-303b4516/ José’s LinkedIn profile: https://www.linkedin.com/in/jose-navarro-betancourt/ About quadraScope Ventures ------------------------------------------------ quadraScope is a venture fund in Boston focusing on the emerging longevity healthcare market. We invest in companies developing pharmaceuticals, diagnostics, software, equipment and devices enabling disease treatment and prevention through biological age reversal. To learn more, please visit our website https://www.quadrascope.com. #longevity #ngs #geneediti
Matter Bio Files First IND for Lm-TT Immunotherapy | Sam Sharifi, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Sam SHARIFI Registration Preliminary program Contact Back to congress SS Sam SHARIFI CSO Matter Bio This speaker will talk about All sessions Apr 2, 2025 6:30 PM 7:15 PM PANEL 7: Q&A – Debate – International Panel AB Ann BELIEN CEO, Rejuvenate Biomed SS Sam SHARIFI CSO Matter Bio EG Eric GILSON Director IRCAN PS Petr SRAMEK Managing Partner, VC Longevity Tech Fund AM Andreas MOGENSEN Astronaut All sessions Powered by 2-3 april 2025 Palais des Festivals de Cannes Program Registration Sponsoring Practical informations Contact Contact us Phone : +33 (0)1.73.28.72.02 Organization 42 rue Barbès 921
Matter Bio files IND for Lm-LLO-TT for PDAC | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib … LLO-TT for PDAC May 20, 2026 No Comments Matter Bio has submitted its first IND application to the FDA for Lm-LLO-TT, the company’s lead therapeutic candidate, seeking to initiate a first-in-human phase I/IIa trial in patients with pancreatic ductal adenocarcinoma (PDAC). BioWorld Science Regulatory Cancer Immuno-oncology IND Popular Stories Today's news in brief BioWorld BioWorld briefs for June 2, 2026. News in brief BioWorld Asia BioWorld Asia briefs for June 2, 2026 ASCO
Pancreatic cancer - Articles | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China C … LLO-TT for PDAC May 20, 2026 No Comments Matter Bio has submitted its first IND application to the FDA for Lm-LLO-TT, the company’s lead therapeutic candidate, seeking to initiate a first-in-human phase I/IIa trial in patients with pancreatic ductal adenocarcinoma (PDAC). Read More Cancer Yantai Rongchang Pharmaceutical reports new KRAS mutant inhibitors May 11, 2026 Yantai Rongchang Pharmaceutical Co. Ltd. has synthesized new GTPase KRAS mutant inhibitors potentially useful
--> Matter Bio Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal Animals Invest
Matter Bio CEO Chris Bradley on DNA Repair and Longevity | Vitalist Bay posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr … ully describes what we do ‘’We are not just teaching; we are building a digital residency where every interaction from a midnight nerdy thought to a formal abstract is a brick in their professional fortress.’’ Research and academic innovation office Gene academy (GemIInieducation) #geneacademy #personalizededucation 5 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Bio-protocol 4,556 followers 1mo Report this post Workflow for Fine-Tuning and Eva
Instagram Instagram Log In Sign Up Close Never miss a post from longevitysummitdublin Sign up for Instagram to stay in the loop. Sign up Log in longevitysummitdublin • Follow More options longevitysummitdublin 10w Speaker spotlight: Christopher Bradley, CEO of Matter Bio. At Longevity Summit Dublin 2026 we focus on aging biology, root causes, and hard open questions. Clear science, honest debate. 24-26 June 2026, Trinity College Dublin. Load more comments No comments yet. Start the conversation. Like Comment Share Save March 18 Log in to like or comment. More posts from longevitysummitdublin C
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Matter Bio Contact Protecting the genome Our Thesis We believe aging is due to accumulation of damage to the genome. Damage As we age, our genome is constantly being damaged by internal and external factors. Occasionally, errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. This DNA damage has been shown to be a central driver of aging. Our goal at Matter Bio is to protect cells from damage and remove cells that are corrupted. This will both prevent and treat a wide array of diseases of ageing an
Matter Bio lands seed funding for longevity therapeutics that preserve… | Sam Sharifi, PhD | 15 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a
Instagram Instagram Log In Sign Up Close Never miss a post from sharelaboslo Sign up for Instagram to stay in the loop. Sign up Log in sharelaboslo • Follow More options sharelaboslo 157w Welcome Sam Sharifi and Matter Bio to ShareLab. Sam is Dutch, a biogerontologist with a PhD from the University of Jena. Matter Bio work within the longevity space with accurate mutation sequencing, improving endogenous DNA repair, removing somatic mutations, and removing overly corrupted cells altogether. Age is inevitable. Aging is not. #longevity #aging #biotech #sharelab #oslo #entrepreneurship Load more
--> LifeSpan Vision Ventures Invests in Matter Bio top of page Home About Portfolio Science Media Press Releases In the News Contact Us More Use tab to navigate through the menu items. LifeSpan Vision Ventures Invests in Matter Bio Oct 23, 2023 2 min read Norwalk, CT – October 23, 2023 – LifeSpan Vision Ventures today announced an investment in Matter Bio, a longevity holding company focused on preserving genome integrity. Central to the company’s philosophy is that as we age, our genome is constantly being damaged by exogenous and endogenous sources. Occasionally errors are missed and incorpo … ome About Portfolio Science Media Contact Subscribe to our press releases Email Submit Thanks for submitting! © 2023 by LifeSpan Vision Ventures bottom of page
Matter Bio-VCBeat VCBeat Health Contact Us Home China Healthcare Select Insights MNC China Lens Vertical Industries Services Partnership Development Market Entry Advisory Ecosystem Engagement Advisory About VCBeat Why VCBeat Log In Home Matter Bio Matter Bio In operation Seed Round Financing Genome Technology Developer Basic Information Matter Bio, co-founded by world-class scientists such as George Church PhD and Jan Vijg PhD, is a longevity holding company focused on preserving genomic integrity. Matter Bio has assembled a world-class team of scientists and executives to help address t
Matter Bio lands seed funding for longevity therapeutics that preserve genomic integrity Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search HAYA … he company also says the funds will help file an Investigational New Drug (IND) application and initiate a Phase 1/2a clinical trial targeting solid cancers. “With our team of rockstar gene editing and sequencing experts, we are uniquely positioned to tackle the loss of genome stability as a driver for aging,” Matter Bio co-founder, Dr Sam Sharifi told us. “Our innovative approach leverages bleeding-edge gene editing and sequencing technologies to develop therapies that resto
Matter Bio Successfully Closes $7M Seed Funding Round | Fitt Insider Articles Podcast Daily Brief Press Releases Reports Subscribe Articles Podcast Daily Brief Reports Press Releases Jobs Board Investor Database Interview Series Wellworthy Work With Us Submit News Sponsor Feedback Contact Search for: Copyright © 2026 Fitt. All rights reserved. Privacy Policy . All Press Releases Press Release Matter Bio Successfully Closes $7M Seed Funding Round Brooklyn, NY / May 29, 2024 / Matter Bio Matter Bio , a pioneering biotech company dedicated to preserving genome integrity and extending healthy huma … Ventures, with participation from quadraScope Ventures and others, and includes grant support from NIH, NCI, and NIEHS. The funds will be utilized to conduct further research into the information theory of aging at a genomic level, which Matter believes contributes significantly to the aging process. The funds will also enable the filing of an IND and the start of a Phase 1/2a clinical trial in solid cancer. Matter Bio tackles the problem of genome instability holistically, a … , please visit matterbio.com . ### Press Contact [email protected] Matter Bio Submit a Press Release Network-driven recruiting for health, fitness, and wellness companies. Fitt Talent Partners is a specialized recruitment firm helping health, fitness, and wellness companies hire world-class talent. Learn More Subscribe to get the most important developments in fitness and wellness. Copyright © 2026 Fitt. All rights reserved. Privacy Policy . Articles Podcast Reports Press R
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … Key Insights Matter Bio has submitted its first Investigational New Drug (IND) application to the FDA for Lm-LLO-TT, an attenuated Listeria monocytogenes-based immunotherapy targeting pancreatic ductal adenocarcinoma. The upcoming Phase 1/2a study will evaluate safety, tolerability, dose optimization, and preliminary anti-tumor activity in patients with one of oncology's most treatment-resistant solid tumors. The platform is designed to stimulate tumor-directed memory i … atter Bio Search company has submitted its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Lm-LLO-TT Search drug , an attenuated Listeria monocytogenes Search term -based immunotherapy targeting pancreatic ductal adenocarcinoma Search disease ( PDAC Search disease ). The submission marks a significant milestone for the San Francisco biotechnology company as it transitions into clinical-stage development. If cleared by the FDA, the … ide additional updates following completion of the FDA's review of the IND application. The company combines advanced tools for measuring DNA damage and genotoxicity with a pipeline of differentiated oncology programs aimed at addressing major unmet needs in cancer. The IND submission represents the culmination of preclinical development work and positions the company to begin clinical evaluation of its lead oncology program. The bacterial immunotherapy approach reflects
Matter Bio Files First IND for Lm-LLO-TT, Advancing First-in-Human Phase 1/2a Study in Pancreatic Cancer Accessibility Statement Skip Navigation Resources Investor Relations Journalists +44 (0)20 7454 5110 Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All Public Company News All Multimedia News View All News Releases Regulatory News D/A/CH Regu … nbsp;today announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lm-LLO-TT , the company's lead therapeutic candidate, for a first-in-human Phase 1/2a clinical trial in patients with pancreatic ductal adenocarcinoma (PDAC). If the IND is cleared by the FDA, the Phase 1/2a study is expected to evaluate the safety, tolerability, dose optimization, and preliminary anti-tumor activity of Lm-LLO-TT … s regarding the submission, review, and potential clearance of Matter Bio's IND application; the planned initiation, design, timing, and conduct of the company's first-in-human Phase 1/2a clinical trial; and the potential therapeutic benefits of Lm-LLO-TT. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks related to … ces Blog Journalists Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Customer Portal Resources Blog Journalists +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookie Settings Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company. --> --
Matter Bio lands seed funding for longevity therapeutics that preserve genomic integrity | Christopher Bradley | 18 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
Christopher Bradley | SynBioBeta Speaker Γ SynBioBeta Speaker Christopher Bradley CEO Matter Bio May 2026, SynBioBeta Speaker Chris Bradley is a serial entrepreneur with a background in neuroscience, cell biology and computer science. He has dedicated his career to founding and translating breakthrough biotechnology and healthcare technology companies that push the boundaries of what is possible. As part of his entrepreneurial journey, Chris has been involved at the earliest stages of company conception; whiteboarding technological solutions and in-sourcing academic IP, all the way … Magnet Ventures Founder & Mng Partner Sushmita Sudarshan Molecular Devices Application Scientist, Assay Dev. Dawn Musil New Bloom Co-founder Nicole Richards Allonnia CEO Andrea Stephany Diaz OncoSwab CEO & Founder Connor Tsuchida Azalea Therapeutics Scientific Co-founder, VP, R&D Max Jamilly Hoxton Farms CEO & Co-founder Juliette Humer Muse Bio Founder & CEO Michael Weiner Abbratech Founder & CEO Kavya Sharman Phase Capital Managing Partner Joshua Gei
Why DNA Damage is Central to Aging — Christopher Bradley, CEO of Matter Bio - Free Radicals | Podcast on Spotify
There has been a recent push towards a biological definition PD, with two novel frameworks published in early 2024. Dr. Victor Fung, MDS President, shares the Society's views and plans to address… | International Parkinson and Movement Disorder Society LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for … s post The research group of Professor Xin-Yuan Fu has discussed the 2025 Nobel Prize-winning Treg research within the broader context of STAT-regulated immune networks. Read more on hLife https://lnkd.in/g7h8W9MU 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Bloomberg Television 100,277 followers 7mo Report this post What used to take an autopsy now takes a blood test. David Rubenstein sits down with Dr. Richard Isaacson to discuss modern me … on of care is where we identify those groups in whom the intervention works and apply it to them and them only. For the rest, we keep looking for a different solution. In TKA, IMO it's becoming clear that since the difference in component alignment between KA and MA for 60% or so of the population is relatively minor, the results are going to be relatively similar. It is the people one or more standard deviations beyond the mean, those with the highest preop ROM and Preop con
Our recent paper from the Chen Lab: Transcription factors exhibit memory, described for the first time in living cells. Congrats to lead author Dr. Won Jung and everyone involved!… | Ace Santiago LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your se
#healthresearch #bioresourcetestimonials | NIHR BioResource LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy P
Alina Su: Can We Really Turn Back Our Biological Clock? (4K) | Méline Liu LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreeme
Is the COVID vaccine still helpful? | Unbiased Science posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s … h, Ana Maretti Garcia, and Jesse Goodrich received an $8 million, five-year NIH grant to launch a new Superfund Research Program Center focused on “forever chemicals” (PFAS), substances found in everyday items that affect nearly every organ in the body and are linked to rare cancers. In collaboration with the USC Viterbi School of Engineering , this new center will focus on finding better ways to remove PFAS from public water and be important step in tackling the growing prob
LifeSpan Vision Ventures investuje do společnosti Matter Bio - Ekonews Přeskočit na obsah Podpořte nás Přihlásit se KOUPIT PŘEDPLATNÉ Hledat: BYZNYS ENERGETIKA DOPRAVA ZEMĚDĚLSTVÍ DEKARBONIZACE ODPADY KLIMATICKÁ ZMĚNA BIODIVERZITA ESG ŽIVOTNÍ STYL EKOPORADNA PODCASTY KOMENTÁŘE BRANDNEWS GREENWASHING FAST FASHION SPECIÁLY CEO o ESG Solution Journalism Jak na emise Udržitelný marketing Udržitelný život Fíla a Píro Žebříčky udržitelnosti Podpořte nás Hledat: BYZNYS ENERGETIKA DOPRAVA ZEMĚDĚLSTVÍ DEKARBONIZACE ODPADY KLIMATICKÁ ZMĚNA BIODIVERZITA ESG ŽIVOTNÍ STYL EKOPORADNA PODCASTY KOMENTÁŘE BRAN
Matter Bio to study longevity secrets with gene therapies | Ryan Cross posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
Matter Bio Announces Landmark Collaboration to Decode Exceptional Longevity at Unprecedented Scale - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and G … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Matter Bio Announces Landmark Collaboration to Decode Exceptional Longevity at Unprecedented Scale April 24, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis of extreme lifes … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejuvenated DNA: Interview with Chris Bradley CEO of Matter Bio - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Chris Bradley: better science … - Razib Khan's Unsupervised Learning - Apple Podcasts Search Home New Top Charts Search April 10 1hr 6min Chris Bradley: better science for longevity Razib Khan's Unsupervised Learning Play Today Razib talks to Chris Bradley, a serial entrepreneur and the CEO and Co-Founder of Matter Bio, a company dedicated to preserving genome integrity and addressing the root causes of aging. With a multidisciplinary background spanning neuroscience, cell biology, and computer science, Bradley aims to translate early-stage biotech concepts into practical therapies that can ex